JP7749542B2 - 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート - Google Patents

癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート

Info

Publication number
JP7749542B2
JP7749542B2 JP2022516159A JP2022516159A JP7749542B2 JP 7749542 B2 JP7749542 B2 JP 7749542B2 JP 2022516159 A JP2022516159 A JP 2022516159A JP 2022516159 A JP2022516159 A JP 2022516159A JP 7749542 B2 JP7749542 B2 JP 7749542B2
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutically acceptable
melanoma
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547331A5 (https=
JP2022547331A (ja
Inventor
ロングカー ジャロッド
ピンチュク アナトリー
フーバー ランドル
ホアン チョンピン
Original Assignee
セレクター・バイオサイエンシズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクター・バイオサイエンシズ・インコーポレイテッド filed Critical セレクター・バイオサイエンシズ・インコーポレイテッド
Publication of JP2022547331A publication Critical patent/JP2022547331A/ja
Publication of JP2022547331A5 publication Critical patent/JP2022547331A5/ja
Priority to JP2025021639A priority Critical patent/JP2025087716A/ja
Priority to JP2025110172A priority patent/JP2025138792A/ja
Application granted granted Critical
Publication of JP7749542B2 publication Critical patent/JP7749542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022516159A 2019-09-12 2020-09-11 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート Active JP7749542B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025021639A JP2025087716A (ja) 2019-09-12 2025-02-13 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2025110172A JP2025138792A (ja) 2019-09-12 2025-06-30 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962899611P 2019-09-12 2019-09-12
US201962899618P 2019-09-12 2019-09-12
US201962899615P 2019-09-12 2019-09-12
US62/899,615 2019-09-12
US62/899,611 2019-09-12
US62/899,618 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US62/946,870 2019-12-11
US202062956844P 2020-01-03 2020-01-03
US202062956907P 2020-01-03 2020-01-03
US62/956,844 2020-01-03
US62/956,907 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025021639A Division JP2025087716A (ja) 2019-09-12 2025-02-13 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2025110172A Division JP2025138792A (ja) 2019-09-12 2025-06-30 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート

Publications (3)

Publication Number Publication Date
JP2022547331A JP2022547331A (ja) 2022-11-11
JP2022547331A5 JP2022547331A5 (https=) 2023-09-22
JP7749542B2 true JP7749542B2 (ja) 2025-10-06

Family

ID=74866023

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022516159A Active JP7749542B2 (ja) 2019-09-12 2020-09-11 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2025021639A Pending JP2025087716A (ja) 2019-09-12 2025-02-13 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2025110172A Pending JP2025138792A (ja) 2019-09-12 2025-06-30 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025021639A Pending JP2025087716A (ja) 2019-09-12 2025-02-13 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2025110172A Pending JP2025138792A (ja) 2019-09-12 2025-06-30 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート

Country Status (12)

Country Link
US (1) US20230066517A1 (https=)
EP (1) EP4028018A4 (https=)
JP (3) JP7749542B2 (https=)
KR (1) KR20220062363A (https=)
CN (1) CN114599371A (https=)
AU (1) AU2020346898B2 (https=)
BR (1) BR112022004482A2 (https=)
CA (1) CA3150991A1 (https=)
IL (1) IL291197A (https=)
MX (1) MX2022003044A (https=)
NZ (1) NZ786360A (https=)
WO (1) WO2021050917A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095515A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles
BR112022006739B1 (pt) * 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁（苏州）生物制药有限公司 修饰的氨基酸及其在adc中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535608A (ja) 2014-11-17 2017-11-30 セレクター・バイオサイエンシズ・インコーポレイテッド 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
JP2019523757A (ja) 2016-05-20 2019-08-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
JP7402172B2 (ja) 2018-04-10 2023-12-20 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン複合体およびそれを標的癌治療に使用する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
WO2017218702A1 (en) * 2016-06-14 2017-12-21 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535608A (ja) 2014-11-17 2017-11-30 セレクター・バイオサイエンシズ・インコーポレイテッド 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
JP2019523757A (ja) 2016-05-20 2019-08-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
JP7402172B2 (ja) 2018-04-10 2023-12-20 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン複合体およびそれを標的癌治療に使用する方法

Also Published As

Publication number Publication date
MX2022003044A (es) 2022-06-02
WO2021050917A1 (en) 2021-03-18
NZ786360A (en) 2025-12-19
EP4028018A4 (en) 2023-10-11
CN114599371A (zh) 2022-06-07
KR20220062363A (ko) 2022-05-16
JP2025138792A (ja) 2025-09-25
IL291197A (en) 2022-05-01
JP2022547331A (ja) 2022-11-11
AU2020346898A1 (en) 2022-04-07
AU2020346898B2 (en) 2026-04-09
BR112022004482A2 (pt) 2022-05-31
JP2025087716A (ja) 2025-06-10
EP4028018A1 (en) 2022-07-20
CA3150991A1 (en) 2021-03-18
US20230066517A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
EP3229810B1 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
JP7749542B2 (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
JP2019196380A (ja) Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物
EP4554929A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
US12496346B2 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
EP3773544B1 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
HK40075720A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
HK40042533A (en) Phospholipid ether analogs as cancer-targeting drug vehicles
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途
HK40042533B (en) Phospholipid ether analogs as cancer-targeting drug vehicles
NZ731669B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250924

R150 Certificate of patent or registration of utility model

Ref document number: 7749542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150